Symbols

KRYS

Krystal Biotech·NASDAQ

--(--)

KRYS fundamentals

KRYS Q4 2025 Earnings

Krystal Biotech (KRYS) released its earnings on Feb 17, 2026: revenue was 107.11M (YoY +17.52%), beat estimates; EPS was 1.7 (YoY +11.84%), beat estimates.

Revenue / YoY

107.11M

+17.52%

EPS / YoY

1.7

+11.84%

Report date

Feb 17, 2026

KRYS Earnings Call Summary for Q4,2025

Revenue Growth: Q4 2025 VYJUVEK revenue $107.1 million (18% YoY), full year $389.1 million (34% YoY). Global expansion to drive 2026 growth, targeting 40+ countries.
Pipeline Momentum: 4 registrational programs advancing; KB407 repeat dosing study starts H1 2026; ocular programs enable home administration.
Financial Strength: $955.9 million cash; 2026 non-GAAP expenses $175-195 million.
Global Expansion: Europe (Italy H2 2026), Japan successful; 90+ patients treated in Europe/Japan. Compliance challenges in Japan due to 2-week prescription limit.

Earnings

EPS

Revenue

Revenue & Expenses

KRYS has released its 2025 Q4 earnings report, with revenue of 107.11M, reflecting a YoY change of 17.52%, and net profit of 51.40M, showing a YoY change of 13.02%. The Sankey diagram below clearly presents KRYS's revenue sources and cost distribution.

Key Indicators

Krystal Biotech (KRYS) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Krystal Biotech (KRYS)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Krystal Biotech (KRYS)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Krystal Biotech (KRYS)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown